Skip to main content

Table 2 Clinical parameters of NHANES III Participants Aged 60 and over by NAFLD status, U.S. 1988–1994

From: Prevalence and long-term outcomes of non-alcoholic fatty liver disease among elderly individuals from the United States

  Aged 60–74 (n = 2095) Aged 75 and over (n = 1176) All (n = 3271)
NAFLD No NAFLD NAFLD No NAFLD
AST (IU/L), mean (SE) 21.75 (0.27)* 19.98 (0.17) 21.28 (0.47) 20.51 (0.17) 20.73 (0.13)
ALT (IU/L), mean (SE) 17.83 (0.39)*† 12.43 (0.25) 14.26 (0.61)* 10.68 (0.20) 13.89 (0.29)
Albumin (g/dL), mean (SE) 4.04 (0.02) 4.02 (0.02) 3.99 (0.01) 3.98 (0.01) 4.02 (0.01)
Platelet (1000 cell/uL), mean (SE) 259.01 (3.75) 261.57 (2.90) 252.90 (2.84) 247.93 (3.39) 257.51 (2.23)
ASCVD, mean (SE) 20.80 (0.32)*† 14.42 (0.26) 44.39 (0.63)* 40.95 (0.66) 24.21 (0.42)
eGFR, mean (SE) 76.20 (0.38)*† 78.40 (0.48) 61.34 (0.96)* 65.79 (0.70) 73.67 (0.33)
HOMA, mean (SE) 7.36 (0.36)* 1.79 (0.03) 7.24 (0.57)* 1.80 (0.02) 4.01 (0.14)
NFS, mean (SE) −0.64 (0.06)*† −1.06 (0.05) 0.07 (0.06) −0.05 (0.05) −0.64 (0.04)
NFS, %
 > 0.676 13.92 (1.08)*† 6.13 (0.80) 31.54 (2.05)* 23.49 (1.21) 14.20 (0.84)
 0.676 - -1.455 60.65 (1.86) 59.50 (1.29) 60.27 (2.14)* 65.78 (1.73) 61.00 (0.88)
 < −1.455 25.43 (2.07)*† 34.38 (1.47) 8.19 (1.11) 10.74 (1.20) 24.80 (1.01)
APRI, mean (SE) 0.28 (0.01)* 0.25 (0.00) 0.28 (0.01) 0.27 (0.00) 0.27 (0.00)
APRI (> 0.7) % 2.05 (0.36)* 0.56 (0.15) 1.77 (0.76) 1.08 (0.25) 1.22 (0.14)
  1. NAFLD was defined as a US FLI score of ≥ 30 in the absence of any other cause of chronic liver disease
  2. *Different from No NAFLD in the same age group (p < .05)
  3. Different from NAFLD Aged 75 and over (p < .05)
  4. Data displayed by weighted percentage/mean (SE)
  5. Abbreviation: CI confidence interval, ASCVD atherosclerotic cardiovascular disease risk score, APRI aspartate aminotransferase to platelet ratio index, FIB-4 fibrosis-4 score, NFS NAFLD fibrosis score, eGFR estimated glomerular filtration rate mL/min/1.73 m2